Merus Labs International Inc (TSE:MSL) (NASDAQ:MSLI) has received an average recommendation of “Hold” from the seven research firms that are presently covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is C$1.99.

A number of equities analysts have issued reports on MSL shares. TD Securities cut their price target on Merus Labs International from C$3.00 to C$1.65 and set a “tender” rating on the stock in a report on Friday, May 12th. Scotiabank increased their price target on Merus Labs International from C$1.25 to C$1.65 and gave the stock a “sector perform” rating in a report on Friday, May 12th. Finally, CIBC increased their price target on Merus Labs International from C$1.40 to C$1.65 in a report on Monday, May 15th.

Merus Labs International (TSE:MSL) traded up 0.61% during mid-day trading on Friday, hitting $1.65. 381,175 shares of the stock were exchanged. Merus Labs International has a 1-year low of $0.95 and a 1-year high of $1.76. The stock has a 50 day moving average price of $1.62 and a 200 day moving average price of $1.25. The company’s market capitalization is $193.64 million.

TRADEMARK VIOLATION WARNING: “Merus Labs International Inc (MSL) Given Average Rating of “Hold” by Brokerages” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/07/14/merus-labs-international-inc-msl-given-average-rating-of-hold-by-brokerages.html.

About Merus Labs International

Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin.

Analyst Recommendations for Merus Labs International (TSE:MSL)

Receive News & Ratings for Merus Labs International Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus Labs International Inc and related companies with MarketBeat.com's FREE daily email newsletter.